Summit Therapeutics (Summit Therapeutics) 3-Year EBITDA Growth Rate : -9.70% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics 3-Year EBITDA Growth Rate?

Summit Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Summit Therapeutics was 56.30% per year. The lowest was -252.80% per year. And the median was -9.75% per year.

Competitive Comparison of Summit Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Summit Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Summit Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's 3-Year EBITDA Growth Rate falls into.

Summit Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Summit Therapeutics (NAS:SMMT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Summit Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (Summit Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Executives

Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan	director, 10 percent owner, officer: See Remarks	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia	director	6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian	officer: VP, Corporate Controller	C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell	officer: Chief Scientific Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham	officer: Chief Clinical Affairs Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov	director, officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142